EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of ketogenic diet in infants with epilepsy: KIWE RCT

Natasha E Schoeler, Louise Marston, Laura Lyons, Sally Halsall, Ruchika Jain, Siobhan Titre-Johnson, Maryam Balogun, Simon J R Heales, Simon Eaton, Michael Orford, Elizabeth Neal, Christin Eltze und 22 weitere

Efficacy and Mechanism Evaluation · 2024-10 · 1-54

DOI: 10.3310/yjtr9895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Efficacy and Mechanism Evaluation, 2024-10. Verfasst von Natasha E Schoeler und 33 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Efficacy and Mechanism Evaluation programme.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many infancy-onset epilepsies have a poor prognosis for seizure control and neurodevelopmental outcome. Ketogenic diets can improve seizures in older children and adults unresponsive to antiseizure medicines. We aimed to determine the effectiveness of the ketogenic diet in reducing seizure frequency compared to further antiseizure medicine in infants with drug-resistant epilepsy.

Methods

In this randomised, open-label trial, 136 infants with epilepsy, aged 1–24 months, with > 4 seizures/week and a previous trial of ≥ 2 antiseizure medicines were recruited from 19 hospitals in the United Kingdom. Following a 1- or 2-week observation period, participants were randomised to receive the classical ketogenic diet or a further antiseizure medicine for 8 weeks, using a computer-generated schedule without stratification. Treatment allocation was concealed from research nurses involved in patient care, but not from participants. The primary outcome was the number of seizures/day recorded during weeks 6–8. All analyses were intention to treat. The trial is registered with the European Union Drug Regulating Authorities Clinical Trials Database (2013-002195-40).

Findings

Between 1 January 2015 and 30 September 2021, 136 eligible infants were randomised. Sixty-one (78%) of 78 assigned to a ketogenic diet and 47 (81%) of 58 assigned to antiseizure medicine had primary outcome data. At 8 weeks, the number of seizures per day, accounting for the baseline rate and randomised group, was not significantly different between groups [median (interquartile range) ketogenic diet 5 (1, 16); antiseizure medicine 3 (2, 11), incidence rate ratio 1.33, 95%, confidence internal 0.84 to 2.11; p = 0.22]. A similar number of infants reported at least one serious adverse event in both groups [antiseizure medicine: 24/56 (43%), ketogenic diet: 40/78 (51%)]. The most common serious adverse events were seizures in both groups. Three infants died during the course of the trial, all of whom were randomised to the ketogenic diet arm; deaths were considered to be unrelated to treatment.

Interpretation

There was no evidence that a ketogenic diet was better than further antiseizure medicine in achieving seizure control in infants with epilepsy. The two treatments were similarly tolerated and a ketogenic diet appears safe to use in infants with epilepsy. A ketogenic diet could be a treatment option in infants whose seizures continue despite trial of two standard antiseizure medicines. Study registration This study was registered as EudraCT 2013-002195-40. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 12/10/18) and is published in full in Efficacy and Mechanism Evaluation ; Vol. 11, No. 16. See the NIHR Funding and Awards website for further award information.

Förderung

  • Efficacy and Mechanism Evaluation programme

Zitieren

APA

Schoeler, N. E., Marston, L., Lyons, L., Halsall, S., Jain, R., Titre-Johnson, S., Balogun, M., Heales, S. J. R., Eaton, S., Orford, M., Neal, E., Eltze, C., Stephen, E., Mallick, A. A., O’Callaghan, F., Agrawal, S., Parker, A., Kirkpatrick, M., Brunklaus, A., …, & Cross, J. H. (2024). Efficacy and safety of ketogenic diet in infants with epilepsy: KIWE RCT. Efficacy and Mechanism Evaluation, 1-54. https://doi.org/10.3310/yjtr9895

Vancouver

Schoeler NE, Marston L, Lyons L, Halsall S, Jain R, Titre-Johnson S, et al. Efficacy and safety of ketogenic diet in infants with epilepsy: KIWE RCT. Efficacy and Mechanism Evaluation. 2024:1-54. doi:10.3310/yjtr9895

BibTeX
@article{Schoeler2024,
  author = {Schoeler, Natasha E and Marston, Louise and Lyons, Laura and Halsall, Sally and Jain, Ruchika and Titre-Johnson, Siobhan and Balogun, Maryam and Heales, Simon J R and Eaton, Simon and Orford, Michael and Neal, Elizabeth and Eltze, Christin and Stephen, Elma and Mallick, Andrew A and O’Callaghan, Finbar and Agrawal, Shakti and Parker, Alasdair and Kirkpatrick, Martin and Brunklaus, Andreas and McLellan, Ailsa and McCullagh, Helen and Samanta, Rajib and Kneen, Rachel and Tan, Hui Jeen and Devlin, Anita and Prasad, Manish and Rattihalli, Rohini and Basu, Helen and Desurkar, Archana and Williams, Ruth and Fallon, Penny and Nazareth, Irwin and Freemantle, Nicholas and Cross, J Helen},
  title = {Efficacy and safety of ketogenic diet in infants with epilepsy: KIWE RCT},
  journal = {Efficacy and Mechanism Evaluation},
  year = {2024},
  pages = {1--54},
  doi = {10.3310/yjtr9895}
}
Kostenlos starten →